Functional imaging of neuroendocrine tumors.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Methods in molecular biology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/978-1-61779-062-1_7PMID 21331931
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An immunohistochemical study

  2013cited by this paper
• [18F]FDG PET/CT in pancreatic neuroendocrine tumours associated with von Hippel Lindau Syndrome

  2009cited by this paper
• Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas.

  2009cited by this paper
• Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.

  2008cited by this paper
• The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.

  2008cited by this paper
• Effects of an antagonist of the bombesin/gastrin-releasing peptide receptor on complete Freund's adjuvant-induced arthritis in rats.

  2008cited by this paper
• Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours

  2008cited by this paper
• Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.

  2008cited by this paper
• Role of PET in medullary thyroid carcinoma.

  2008cited by this paper
• Comparison of 6-18F-Fluorodopamine PET with 123I-Metaiodobenzylguanidine and 111In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic Pheochromocytoma

  2008cited by this paper
• Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

  2007cited by this paper
• Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels

  2007cited by this paper
• The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome.

  2007cited by this paper
• Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours

  2007cited by this paper
• Nuclear imaging of neuroendocrine tumours.

  2007cited by this paper
• Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma

  2007cited by this paper
• [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings.

  2006cited by this paper
• Fluorodeoxyglucose Positron Emission Tomography Improve Clinical Decision Making in Suspected Pheochromocytoma

  2006cited by this paper
• Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.

  2006cited by this paper
• Functional imaging of neuroendocrine tumours with PET

  2006cited by this paper
• Integrated PET/CT: current applications and future directions.

  2006cited by this paper
• Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.

  2005cited by this paper
• Whole-Body 11C-5-Hydroxytryptophan Positron Emission Tomography as a Universal Imaging Technique for Neuroendocrine Tumors : Comparison with Somatostatin Receptor Scintigraphy and Computed Tomography

  2005cited by this paper
• Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography.

  2005cited by this paper
• Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography

  2005cited by this paper
• Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.

  2004cited by this paper
• Pheochromocytomas: detection with 11C hydroxyephedrine PET.

  2004cited by this paper
• PET in the Diagnosis of Neuroendocrine Tumors

  2004cited by this paper
• Functional imaging of endocrine tumors: role of positron emission tomography.

  2004cited by this paper
• Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.

  2003cited by this paper
• 18F-DOPA positron emission tomography for the detection of glomus tumours

  2003cited by this paper
• Peptide receptors as molecular targets for cancer diagnosis and therapy.

  2003cited by this paper
• Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma.

  2003cited by this paper
• 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma.

  2002cited by this paper
• Pheochromocytomas: detection with 18F DOPA whole body PET--initial results..

  2002cited by this paper
• Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67

  2002cited by this paper
• Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells

  2002cited by this paper
• 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels

  2001cited by this paper
• PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.

  2001cited by this paper
• Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study

  2001cited by this paper
• Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors.

  2001cited by this paper
• Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data

  2001cited by this paper
• A combined PET/CT scanner for clinical oncology.

  2000cited by this paper
• PET Imaging of Adrenal Cortical Tumors with the 11 ß-Hydroxylase Tracer 11 C-Metomidate

  2000cited by this paper
• PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate.

  2000cited by this paper
• Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen.

  1998cited by this paper
• Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors.

  1998cited by this paper
• In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors.

  1998cited by this paper
• Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours

  1997cited by this paper
• The somatostatin receptor family.

  1995cited by this paper
• PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma.

  1992cited by this paper
• Somatostatin-receptor imaging in the localization of endocrine tumors.

  1990cited by this paper
• Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin.

  1989cited by this paper
• The APUD concept and hormone production.

  1980cited by this paper
• Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid and ultimobranchial C cells and calcitonin

  1968cited by this paper
• THE CLASSIFICATION OF CARCINOID TUMOURS

  1963cited by this paper
• The classification of carcinoid tum ours.

  1963cited by this paper
• Die Klassifizierung der Karzinoide

  1957cited by this paper

• Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology—From Bench to Bedside

  2025cites this paper
• Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors

  2024cites this paper
• Somatostatin Analog-Based Radiopharmaceuticals for Molecular Imaging and Therapy of Neuroendocrine Tumors

  2022cites this paper
• New Directions in Imaging Neuroendocrine Neoplasms

  2021cites this paper
• Automated GMP compliant production of [18F]AlF-NOTA-octreotide

  2020cites this paper
• Validierung der Aspherizität als bildgebender Prognoseparameter für Patienten mit GEP-NEN und Behandlung mittels PRRT

  2017influential citation
• Diagnostic Applications of Nuclear Medicine: Colorectal Cancer

  2016cites this paper
• Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients

  2016cites this paper
• Ga-68 Labeled Somatostatin Analogs Positron Emission Tomography/ Computed Tomography in Gastroenteropancreatic Neuroendocrine Tumors

  2014cites this paper
• The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature.

  2014cites this paper
• Is there a role for PET-CT and SPECT-CT in pediatric oncology?

  2013cites this paper
• How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta-analysis

  2012cites this paper
• Current and future aspects of nuclear molecular therapies: a model of theranostics.

  2011cites this paper